Sammendrag
Meibomian gland dysfunction (MGD) is the most common cause of dry eye disease (DED). In this
study, we aimed to compare the effects of eyelid warming treatment using either TheraPearl Eye
Mask (Bausch & Lomb Inc., New York, USA) or Blephasteam (Spectrum Thea Pharmaceuticals LTD,
Macclesfield, UK) in a Norwegian population with mild to moderate MGD-related DED. An open label,
randomized comparative trial with seventy patients (49 females, 21 males; mean age 53.6 years).
Patients were randomly assigned to treatment with Blephasteam (n = 37) or TheraPearl (n = 33). All
received a hyaluronic acid based artificial tear substitute (Hylo-Comod, Ursapharm, Saarbrücken,
Germany). Patients were examined at baseline, and at three and six months initiation of treatment.
Treatment efficacy was primarily evaluated by fluorescein breakup time (FBUT) and Ocular Surface
Disease Index (OSDI) scores. Other outcome measures included ocular surface staining (OSS),
Schirmer’s test, and meibomian quality and expressibility. Baseline parameter values did not differ
between the groups. After six months of treatment, Blephasteam improved FBUT by 3.9 s (p
Vis fullstendig beskrivelse